An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B.
# T1 Protein S1 145 148 145 148 Tat
$ T1 Protein S1 145 148 145 148 Tat
@ T3 Negative_regulation S1 95 105 95 105 prevention
@ T4 Entity S1 109 116 109 116 nuclear
@ T5 Localization S1 117 130 117 130 translocation
% E1 Negative_regulation:T3 Theme:E2
% E2 Localization:T5 Theme:T1 ToLoc:T4

The efficacy of o,o'-bismyristoyl thiamine disulfide (BMT) was examined in detail against HIV-1 laboratory isolates (HTLV-IIIB, JRFL, and MN), primary isolates (KMT and KMO), and simian immunodeficiency virus (SIVmac251) in vitro.

BMT inhibited the replication of HIV-1 in both laboratory and primary isolates in vitro.

In addition, BMT exhibited antiviral activity against SIVmac251.

Minimizing energy studies of BMT structure reveal that a trans-disulfide of thiamine (holo drug) disulfide (TDS, protodrug) is allosterically transited to the reactive twisted disulfide of BMT (allo drug) by o,o'-bismyristoyl esterification of TDS.

BMT inhibits nuclear translocation of both HIV-1 transactivator (TAT) and the cellular transcriptional nuclear factor-KB (NF-kappa B), resulting in the suppression of HIV-1 replication.
# T2 Protein S6 65 68 865 868 TAT
$ T2 Protein S6 65 68 865 868 TAT
@ T6 Negative_regulation S6 4 12 804 812 inhibits
@ T7 Entity S6 13 20 813 820 nuclear
@ T8 Localization S6 21 34 821 834 translocation
% E3 Negative_regulation:T6 Theme:E4
% E4 Localization:T8 Theme:T2 ToLoc:T7

